J-104,129

J-104,129
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

J-104,129 is a chemical compound that acts as a potent and selective phosphodiesterase (PDE) inhibitor. It is primarily used in scientific research to study the role of PDEs in various physiological processes.

Pharmacology

J-104,129 is known for its high selectivity towards phosphodiesterase 4 (PDE4) enzymes. PDE4 is an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a secondary messenger involved in many biological processes. By inhibiting PDE4, J-104,129 increases the levels of cAMP within cells, which can lead to various downstream effects.

Mechanism of Action

The primary mechanism of action of J-104,129 is the inhibition of PDE4, which prevents the hydrolysis of cAMP to AMP. This results in elevated intracellular cAMP levels, leading to the activation of protein kinase A (PKA) and other cAMP-dependent pathways. These pathways are involved in regulating inflammation, immune responses, and other cellular processes.

Therapeutic Potential

While J-104,129 is not used clinically, its ability to modulate cAMP levels makes it a valuable tool in research. PDE4 inhibitors have potential therapeutic applications in treating inflammatory diseases, depression, and chronic obstructive pulmonary disease (COPD).

Research Applications

J-104,129 is used extensively in preclinical studies to explore the role of PDE4 in various diseases. It helps in understanding the pathophysiology of conditions where cAMP signaling is disrupted. Researchers use J-104,129 to investigate new therapeutic targets and to develop novel treatments for diseases associated with PDE4 dysregulation.

Safety and Toxicology

As with many research chemicals, the safety profile of J-104,129 is not fully established. It is primarily used in controlled laboratory settings, and its effects in humans are not well-documented. Researchers handling J-104,129 should follow appropriate safety protocols to minimize exposure and potential risks.

Also see

• Phosphodiesterase inhibitor
• Cyclic adenosine monophosphate
• Protein kinase A
• Inflammatory diseases

This article is a stub related to pharmacology. You can help WikiMD by expanding it!